214 related articles for article (PubMed ID: 10713444)
41. The dynamics of DNA topoisomerase IIalpha in living cells.
Daum JR; Mo YY; Gorbsky GJ
Methods Mol Biol; 2009; 582():233-44. PubMed ID: 19763954
[TBL] [Abstract][Full Text] [Related]
42. Role of proteasomal degradation in the cell cycle-dependent regulation of DNA topoisomerase IIalpha expression.
Salmena L; Lam V; McPherson JP; Goldenberg GJ
Biochem Pharmacol; 2001 Apr; 61(7):795-802. PubMed ID: 11274964
[TBL] [Abstract][Full Text] [Related]
43. Topoisomerase IIalpha binding domains of adenomatous polyposis coli influence cell cycle progression and aneuploidy.
Wang Y; Coffey RJ; Osheroff N; Neufeld KL
PLoS One; 2010 Apr; 5(4):e9994. PubMed ID: 20368985
[TBL] [Abstract][Full Text] [Related]
44. Xenopus NF-Y pre-sets chromatin to potentiate p300 and acetylation-responsive transcription from the Xenopus hsp70 promoter in vivo.
Li Q; Herrler M; Landsberger N; Kaludov N; Ogryzko VV; Nakatani Y; Wolffe AP
EMBO J; 1998 Nov; 17(21):6300-15. PubMed ID: 9799238
[TBL] [Abstract][Full Text] [Related]
45. Ras stimulates DNA topoisomerase II alpha through MEK: a link between oncogenic signaling and a therapeutic target.
Chen G; Templeton D; Suttle DP; Stacey DW
Oncogene; 1999 Nov; 18(50):7149-60. PubMed ID: 10597316
[TBL] [Abstract][Full Text] [Related]
46. DNA Topoisomerase IIα contributes to the early steps of adipogenesis in 3T3-L1 cells.
Jacobsen RG; Mazloumi Gavgani F; Mellgren G; Lewis AE
Cell Signal; 2016 Oct; 28(10):1593-603. PubMed ID: 27404349
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
Satterwhite DJ; White RL; Matsunami N; Neufeld KL
Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
[TBL] [Abstract][Full Text] [Related]
48. Functional interaction between human topoisomerase IIalpha and retinoblastoma protein.
Bhat UG; Raychaudhuri P; Beck WT
Proc Natl Acad Sci U S A; 1999 Jul; 96(14):7859-64. PubMed ID: 10393912
[TBL] [Abstract][Full Text] [Related]
49. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
50. Autoregulation of mouse histone deacetylase 1 expression.
Schuettengruber B; Simboeck E; Khier H; Seiser C
Mol Cell Biol; 2003 Oct; 23(19):6993-7004. PubMed ID: 12972616
[TBL] [Abstract][Full Text] [Related]
51. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
52. Histone deacetylase inhibitors stimulate mitochondrial HMG-CoA synthase gene expression via a promoter proximal Sp1 site.
Camarero N; Nadal A; Barrero MJ; Haro D; Marrero PF
Nucleic Acids Res; 2003 Mar; 31(6):1693-703. PubMed ID: 12626711
[TBL] [Abstract][Full Text] [Related]
53. NF-M trans-activates the human DNA topoisomerase II alpha promoter independently of c-Myb in HL-60 cells.
Brandt TL; Kroll DJ
Leuk Res; 1997 Aug; 21(8):711-20. PubMed ID: 9379678
[TBL] [Abstract][Full Text] [Related]
54. Identification of promoter elements responsible for transcriptional inhibition of polo-like kinase 1 and topoisomerase IIalpha genes by p21(WAF1/CIP1/SDI1).
Zhu H; Chang BD; Uchiumi T; Roninson IB
Cell Cycle; 2002 Jan; 1(1):59-66. PubMed ID: 12429910
[TBL] [Abstract][Full Text] [Related]
55. Two differentially spliced forms of topoisomerase IIalpha and beta mRNAs are conserved between birds and humans.
Petruti-Mot AS; Earnshaw WC
Gene; 2000 Nov; 258(1-2):183-92. PubMed ID: 11111056
[TBL] [Abstract][Full Text] [Related]
56. Genomic structure and chromosomal mapping of the gene coding for ICBP90, a protein involved in the regulation of the topoisomerase IIalpha gene expression.
Hopfner R; Mousli M; Garnier JM; Redon R; du Manoir S; Chatton B; Ghyselinck N; Oudet P; Bronner C
Gene; 2001 Mar; 266(1-2):15-23. PubMed ID: 11290415
[TBL] [Abstract][Full Text] [Related]
57. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.
Duan H; Heckman CA; Boxer LM
Mol Cell Biol; 2005 Mar; 25(5):1608-19. PubMed ID: 15713621
[TBL] [Abstract][Full Text] [Related]
58. Ectopic expression of human topoisomerase IIalpha fragments and etoposide resistance in mammalian cells.
Ernst AI; Soltermann A; Sigrist JA; Widmer L; Gasser SM; Stahel RA
Int J Cancer; 2000 Oct; 88(1):99-107. PubMed ID: 10962446
[TBL] [Abstract][Full Text] [Related]
59. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding.
Hu J; Colburn NH
Mol Cancer Res; 2005 Feb; 3(2):100-9. PubMed ID: 15755876
[TBL] [Abstract][Full Text] [Related]
60. Expression of Y box-binding protein-1 correlates with DNA topoisomerase IIalpha and proliferating cell nuclear antigen expression in lung cancer.
Gu C; Oyama T; Osaki T; Kohno K; Yasumoto K
Anticancer Res; 2001; 21(4A):2357-62. PubMed ID: 11724293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
